Patent Assignment
Reel/Frame 059787/0758
Change of Name
Recorded: 2022-04-25
Pages: 6
Assignor
SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Executed: 2022-04-01
Assignee
SUMITOMO PHARMA ONCOLOGY, INC.
640 MEMORIAL DRIVE, CAMBRIDGE, MASSACHUSETTS, 02139
Covered Properties
(43)
Imidazo[1,2-B]Pyridazine and Pyrazolo[1,5-a]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
PCT:
PCT/US2007/083773 ↗
Heterocyclic Protein Kinase Inhibitors
PCT:
PCT/US2012/047685 ↗
JAK2 and ALK2 Inhibitors and Methods for Their Use
PCT:
PCT/US2014/026595 ↗
Pim Kinase Inhibitors for Treatment of Myeloproliferative Neoplasms and Fibrosis Associated with Cancer
PCT:
PCT/US2019/027217 ↗
Methods for Treating Diseases Associated with Abnormal ACVR1 Expression and ACVR1 Inhibitors for Use in the Same
PCT:
PCT/US2019/043738 ↗
ALK5 Inhibitors for Treating Myelodysplastic Syndrome
PCT:
PCT/US2020/013214 ↗
Formulations Comprising Heterocyclic Protein Kinase Inhibitors
PCT:
PCT/US2020/017981 ↗
Axl Inhibitor Formulations
PCT:
PCT/US2020/054032 ↗
Solid Dose Pharmaceutical Composition
PCT:
PCT/US2020/061629 ↗
Imidazo[1,2-Beta]Pyridazine and Pyrazolo[1,5-Alpha]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
Methods and Compounds for Treating Pim-1 Kinase-Expressing Cancer Cells
Application:
12/785,322 →
Publication:
US 2010/0227861
Imidazo[1,2-B]Pyridazine and Pyrazolo[1,5-a]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES AS PROTEIN KINASE INHIBITORS
JAK2 and ALK2 Inhibitors and Methods for Their Use
Substituted Imidazo[1,2-B]Pyridazines as Protein Kinase Inhibitors
Substituted Imidazo[1,2-B]Pyridazines as Protein Kinase Inhibitors
JAK2 and ALK2 Inhibitors and Methods for Their Use
Substituted Imidazo[1,2-B]Pyridazines as Protein Kinase Inhibitors
Methods for Treating Diseases Associated with Abnormal ACVR1 Expression and ACVR1 Inhibitors for Use in the Same
ALK5 Inhibitors for Treating Myelodysplastic Syndrome
Application:
16/740,219 →
Publication:
US 2020/0323851
Formulations Comprising Heterocyclic Protein Kinase Inhibitors
JAK2 and ALK2 Inhibitors and Methods for Their Use
Application:
16/930,261 →
Publication:
US 2021/0070715
Pim Kinase Inhibitors for Treatment of Myeloproliferative Neoplasms and Fibrosis Associated with Cancer
Application:
17/047,383 →
Publication:
US 2021/0113562
Substituted Imidazo[1,2-B]Pyridazines as Protein Kinase Inhibitors
Application:
17/090,857 →
Publication:
US 2021/0238183
IMIDAZO[1,2-b]PYRIDAZINE AND PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
Application:
60/864,566 →
IMIDAZO[1,2-b]PYRIDAZINE AND PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
Application:
60/892,523 →
IMIDAZO[1,2-b]PYRIDAZINE AND PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
Application:
60/957,988 →
[1,2,4]Triazolo[4,3-A]Pyridine Derivatives and Their Use as Protein Kinase Inhibitors
Application:
61/510,207 →
Imidazo[1,2-B]Pyridazine and Pyrazolo[1,5-a]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
Application:
61/608,028 →
Imidazo[1,2-B]Pyridazine and Pyrazolo[1,5-a]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
Application:
61/632,826 →
Imidazo[1,2-B]Pyridazine and Pyrazolo[1,5-a]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
Application:
61/632,834 →
Publication:
US 2012/0058997
JAK2 and ALK2 Inhibitors and Methods for Their Use
Application:
61/785,460 →
Pim Kinase Inhibitors for Treatment of Myeloproliferative Neoplasms
Application:
62/657,540 →
Pim Kinase Inhibitors for Treatment of Myeloproliferative Neoplasms
Application:
62/657,563 →
Methods for Treating Diseases Associated with Abnormal ACVR1 Expression and ACVR1 Inhibitors for Use in the Same
Application:
62/703,862 →
Pim Kinase Inhibitors for Treatment of Myeloproliferative Neoplasms and Fibrosis Associated with Cancer
Application:
62/743,469 →
Pim Kinase Inhibitors for Treatment of Myeloproliferative Neoplasms and Fibrosis Associated with Cancer
Application:
62/753,023 →
Pim Kinase Inhibitors for Treatment of Myeloproliferative Neoplasms
Application:
62/753,025 →
ALK5 Inhibitors for Treating Myelodysplastic Syndrome
Application:
62/790,961 →
Formulations Comprising Heterocyclic Protein Kinase Inhibitors
Application:
62/804,556 →
Formulations Comprising Heterocyclic Protein Kinase Inhibitors
Application:
62/925,153 →
Solid Dose Pharmaceutical Composition
Application:
62/939,489 →
Formulations Comprising Heterocyclic Protein Kinase Inhibitors
Application:
62/962,833 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Mar 2, 2007
From: BEARSS, DAVID J.; VANKAYALAPATI, HARIPRASAD; LIU, XIAO-HUI
To: SUPERGEN, INC.
Reel/Frame 018954/0792 →
Assignment of Assignor's Interest
Mar 28, 2008
From: BEARSS, DAVID J.; LIU, XIAO-HUI; VANKAYALAPATI, HARIPRASAD; XU, YONG
To: SUPERGEN, INC.
Reel/Frame 020721/0348 →
Merger/Name Change
Feb 22, 2012
From: SUPERGEN, INC.
To: ASTEX PHARMACEUTICALS. INC.
Reel/Frame 027747/0334 →
Assignment of Assignor's Interest
Jul 26, 2012
From: ASTEX PHARMACEUTICALS, INC.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 028650/0717 →
Assignment of Assignor's Interest
Aug 12, 2014
From: XU, YONG; BRENNING, BENJAMIN GARY; KULTGEN, STEVEN G.; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 033521/0153 →
Assignment of Assignor's Interest
Mar 22, 2016
From: MOLLARD, ALEXIS; WARNER, STEVEN L.; FLYNN, GARY A.; VANKAYALAPATI, HARIPRASAD
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 038068/0314 →
Security Interest
Nov 17, 2016
From: TOLERO PHARMACEUTICALS, INC.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 040362/0884 →
Assignment of Assignor's Interest
May 15, 2019
From: FOULKS, JASON MARC; WARNER, STEVEN L.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 049180/0782 →
Assignment of Assignor's Interest
Oct 3, 2019
From: WARNER, STEVEN L.; BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 050612/0260 →
Assignment of Assignor's Interest
Oct 3, 2019
From: ARIKAWA, YUKA
To: SUMITOMO DAINIPPON PHARMA COMPANY, LIMITED
Reel/Frame 050612/0386 →
Assignment of Assignor's Interest
Oct 3, 2019
From: SUMITOMO DAINIPPON PHARMA COMPANY, LIMITED
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 050612/0563 →
Assignment of Assignor's Interest
Oct 3, 2019
From: WARNER, STEVEN L.; BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 050611/0952 →
Assignment of Assignor's Interest
Oct 3, 2019
From: ARIKAWA, YUKA
To: SUMITOMO DAINIPPON PHARMA COMPANY, LIMITED
Reel/Frame 050612/0115 →
Assignment of Assignor's Interest
Oct 3, 2019
From: SUMITOMO DAINIPPON PHARMA COMPANY, LIMITED
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 050612/0176 →
Assignment of Assignor's Interest
Jan 24, 2020
From: BEARSS, DAVID J.; WARNER, STEVEN L.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 051613/0030 →
Assignment of Assignor's Interest
Mar 6, 2020
From: WARNER, STEVEN L.; SIDDIQUI-JAIN, ADAM; FLYNN, PAUL
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 052035/0192 →
Assignment of Assignor's Interest
Apr 27, 2020
From: XU, YONG; BRENNING, BENJAMIN GARY; KULTGEN, STEVEN G.; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 052500/0211 →
Assignment of Assignor's Interest
Jun 30, 2020
From: MOLLARD, ALEXIS; WARNER, STEVEN L.; FLYNN, GARY A.; VANKAYALAPATI, HARIPRASAD
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 053091/0872 →
Assignment of Assignor's Interest
Jul 10, 2020
From: MOLLARD, ALEXIS; WARNER, STEVEN L.; FLYNN, GARY A.; VANKAYALAPATI, HARIPRASAD
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 053173/0591 →
Merger
Jul 10, 2020
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 053172/0940 →
Merger
Jul 10, 2020
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 053172/0344 →
Merger
Jul 10, 2020
From: SUPERGEN, INC.
To: ASTEX PHARMACEUTICALS, INC.
Reel/Frame 053174/0873 →
Assignment of Assignor's Interest
Jul 10, 2020
From: BEARSS, DAVID J.; LIU, XIAO-HUI; VANKAYALAPATI, HARIPRASAD; XU, YONG
To: SUPERGEN, INC.
Reel/Frame 053175/0064 →
Change of Name
Jul 10, 2020
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 053184/0663 →
Change of Name
Jul 10, 2020
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 053184/0718 →